应用人胎儿脾LAK细胞治疗62例晚期恶性肿瘤病人的疗效观察

采用人胎儿脾ＬＡＫ细胞治疗６２例晚期恶性肿瘤病人。结果表明人胎儿脾ＬＡＫ细胞的临床应用安全可行，多数病人在治疗期间一般状况得到改善。总缓解率为（ＰＲ）２２．５８％，平均缓解时间为１５．９５个月。缓解率与克氏评分和接受４次疗程的ＩＬ－２／ＬＡＫ细胞用量有关。在１８．４个月的治疗期间，死亡率为２０．９７％，平均生存期为１６．５０个月。ＩＬ－２／ＬＡＫ细胞对肾癌、黑色素瘤、结肠癌、肺癌和肝癌的转移灶有较好疗效，对原发灶也有一定作用。

Evaluation of the Treatment of 62 Patients with Advanced Cancer by Using Lymphokine-activated Killer Cells plus Interleukin-2

Sixty two patients with advanced cancer were treated with lym phokine-activated killer(LAK)cells derived from the fetal spleen along with inter leukin-2(IL-2).It was shown that this kind of LAK cells is as reliable and effective as others.A partial response(PR)rate of 22.58% was achieved.As for cancer of kidney,melanoma,liver,lung,colon,the figures were 66.67%,50.00%,25.00%,19.43%,16.67% respectively.The median duration of PR was 15.95 months.The performance status before and during the treatment course of IL-2/LAK cells were important factor affecting the remission.The mortality was 20.97%.This im munotherapeutic approach can result in tumour regression,and good effect on metastatic lesion as well in some patients for whom no other effective therapy is available as yet.Further random trial is justified.